Clavis Pharma Successfully Completes Clinical Phase I Study in Haematology

Clavis Pharma has announced that an important milestone has been reached in its haematology program with ELACYT™.

ELACYT is in development for the treatment of haematological cancers (blood cancers) as well as for solid tumours.

The phase I part of the ongoing clinical phase I/II study within haematological cancers has been successfully completed.

The maximal tolerated dose (MTD) has been determined and clinical activity has been reported.

The phase II part will start when the dose and regimen has been decided by the international clinical expert group by the end of April 2008.

In this ongoing phase I/II study 75 patients have been treated to date and have tolerated ELACYT well at doses up to 2500 mg/m²/day.

Clavis Pharma ASA

Clavis Pharma ASA
Oncology drug development

Downloads

DownloadFull Press Release

Latest News

MVM Partners LLP Closes Fund V

MVM Partners announces the closing of a $325 million healthcare fund, MVM V.

HLS Therapeutics announces Health Canada approval for Vascepa® to reduce the risk of cardiovascular events

HLS Therapeutics announces that Health Canada has approved the use of Vascepa® to reduce the risk of cardiovascular events in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor.

Biotheranostics launches Not Another Minute campaign for its Breast Cancer Index® test

Biotheranostics announces the launch of its Not Another minute campaign, revealing how Breast Cancer Index is changing the game for early-stage, hormone receptor-positive breast cancer patients.

Vertos MOTION study enrollment complete

Vertos Medical completes enrollment in MOTION study of mild® procedure, a minimally invasive treatment for lumbar spinal stenosis

HLS Therapeutics announces Health Canada grants medical device license for CSAN PRONTO

HLS Therapeutics Inc. announces that Health Canada has granted a medical device license for the Athelas One WBC System, marketed as CSAN PRONTO, for use as a point-of-care device indicated for quantitative determination of white blood cells and neutrophil percentages in capillary or venous whole blood.

Valneva completes recruitment for phase 2 studies of its Lyme Disease vaccine candidate VLA15

Valneva has announced that it has completed patient recruitment of the Phase 2 studies for its Lyme disease vaccine candidate, VLA15.